Molecular diagnostics company Nanosphere, Inc., is presenting new performance and clinical outcome data for three Verigene multiplex infectious disease tests at the American Society for Microbiology (ASM) conference in Boston, which will conclude tomorrow. Nanosphere is telling its story via a dozen poster presentations.
Among the 12 posters being presented, seven highlight performance of the recently FDA-cleared Verigene Gram-Negative Blood Culture Test (BC-GN) and the importance of rapid detection of multidrug-resistant gram-negative bacteria. Four posters highlight clinical outcomes data for the FDA-cleared Verigene Gram-Positive Blood Culture Test (BC-GP). The remaining poster compares the performance of the FDA-cleared Verigene Respiratory Virus Plus (RV+) Test with two other commercially available assays for detection of influenza and respiratory syncytial virus (RSV).
The Verigene System uses Nanosphere's core proprietary gold nanoparticle chemistry to offer highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The System rapidly and accurately detects infectious pathogens and drug resistance markers by targeting conserved genetic regions of a bacterium or virus. Currently, the multiplexed Verigene assays target infections of the blood, respiratory tract, and gastrointestinal tract.
Nanosphere spokespersons are stressing to conference attendees that the information gathered from Verigene test results enables clinicians to make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy, and reduced spread of antibiotic resistance. Learn more about the Verigene System.
Read more
